PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
Oligometastases
PSMA-PET
Stereotactic body radiotherapy
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
16
12
2021
accepted:
09
02
2022
pubmed:
11
3
2022
medline:
21
5
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
To assess the outcomes of a cohort of bone oligometastatic prostate cancer patients treated with PSMA-PET guided stereotactic body radiotherapy (SBRT). From April 2017 to January 2021, 40 patients with oligorecurrent prostate cancer detected by PSMA-PET were treated with SBRT for bone oligometastases. Concurrent androgen deprivation therapy was an exclusion criterion. A total of 56 prostate cancer bone oligometastases were included in the present analysis. In 28 patients (70%), oligometastatic disease presented as a single lesion, two lesions in 22.5%, three lesions in 5%, four lesions in 2.5%. 30.3% were spine-metastases, while 69.7% were non-spine metastases. SBRT was delivered for a median dose of 30 Gy (24-40 Gy) in 3-5 fractions, with a median EQD
Identifiants
pubmed: 35266063
doi: 10.1007/s10585-022-10157-8
pii: 10.1007/s10585-022-10157-8
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-448Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Testa U, Castelli G, Pelosi E (2019) Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. Medicines 6(3):82. https://doi.org/10.3390/medicines6030082
doi: 10.3390/medicines6030082
pmcid: 6789661
Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S (2021) Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18(2):79–92. https://doi.org/10.1038/s41585-020-00400-w
doi: 10.1038/s41585-020-00400-w
pubmed: 33328650
Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22(1):98–106. https://doi.org/10.1016/S1470-2045(20)30537-4
doi: 10.1016/S1470-2045(20)30537-4
pubmed: 33387498
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P (2020) Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol 21(1):e18–e28. https://doi.org/10.1016/S1470-2045(19)30718-1
doi: 10.1016/S1470-2045(19)30718-1
pubmed: 31908301
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853
doi: 10.1200/JCO.2017.75.4853
pubmed: 29240541
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ (2016) Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34(14):1652–1659. https://doi.org/10.1200/JCO.2015.65.7270
doi: 10.1200/JCO.2015.65.7270
pubmed: 26951312
pmcid: 4872320
Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G (2014) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74(3):297–305. https://doi.org/10.1002/pros.22750
doi: 10.1002/pros.22750
pubmed: 24395565
Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025. https://doi.org/10.1016/j.cell.2015.10.025
doi: 10.1016/j.cell.2015.10.025
Ku SY, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol 16(11):645–654. https://doi.org/10.1038/s41585-019-0237-8
doi: 10.1038/s41585-019-0237-8
pubmed: 31591549
pmcid: 6858516
Evans R, Loeb A, Kaye KS, Cher ML, Martin ET (2017) Infection-related hospital admissions after prostate biopsy in United States men. Open Forum Infect Dis. 4(1):ofw265
doi: 10.1093/ofid/ofw265
Mullane SA, Van Allen EM (2016) Precision medicine for advanced prostate cancer. Curr Opin Urol 26(3):231–239. https://doi.org/10.1097/MOU.0000000000000278.PMID:26909474;PMCID:PMC4955574
doi: 10.1097/MOU.0000000000000278.PMID:26909474;PMCID:PMC4955574
pubmed: 26909474
pmcid: 4955574
Mazzoni A, Oddo CM, Valle G, Camboni D, Strauss I, Barbaro M, Barabino G, Puddu R, Carboni C, Bisoni L, Carpaneto J, Vecchio F, Petrini FM, Romeni S, Czimmermann T, Massari L, di Iorio R, Miraglia F, Granata G, Pani D, Stieglitz T, Raffo L, Rossini PM, Micera S (2020) Morphological neural computation restores discrimination of naturalistic textures in trans-radial amputees. Sci Rep 10(1):527. https://doi.org/10.1038/s41598-020-57454-4.Erratum.In:SciRep.2021Aug11;11(1):16662.PMID:31949245;PMCID:PMC6965126
doi: 10.1038/s41598-020-57454-4.Erratum.In:SciRep.2021Aug11;11(1):16662.PMID:31949245;PMCID:PMC6965126
pubmed: 31949245
pmcid: 6965126
Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, Sheehan J, Gerszten PC, Chang E, Gibbs I, Soltys S, Sahgal A, Deasy J, Flickinger J, Quader M, Mindea S, Yamada Y (2012) International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 83(5):e597-605. https://doi.org/10.1016/j.ijrobp.2012.03.009
doi: 10.1016/j.ijrobp.2012.03.009
pubmed: 22608954
Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, Niemierko A, Soltys SG, Tomé WA, Wong CS, Yorke E, Grimm J, Jackson A (2019) Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys S0360–3016(19):33862–33863. https://doi.org/10.1016/j.ijrobp.2019.09.038
doi: 10.1016/j.ijrobp.2019.09.038
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tomé WA, Verellen D, Wang L, Yin FF (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37(8):4078–4101. https://doi.org/10.1118/1.3438081
doi: 10.1118/1.3438081
pubmed: 20879569
Moraes FY, Chen X, Yan M et al (2020) Evolving role of stereotactic body radiation therapy in the management of spine metastases: defining dose and dose constraints. Neurosurg Clin N Am 31(2):167–189. https://doi.org/10.1016/j.nec.2019.12.001
doi: 10.1016/j.nec.2019.12.001
pubmed: 32147009
Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles AC, Ottewell PD, Dear TN, Holen I, Croucher PI, Eaton CL (2014) Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. J Bone Miner Res 29(12):2688–2696. https://doi.org/10.1002/jbmr.2300
doi: 10.1002/jbmr.2300
pubmed: 24956445
Zhang X (2019) Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Cancer Commun (Lond) 39(1):76. https://doi.org/10.1186/s40880-019-0425-1
doi: 10.1186/s40880-019-0425-1
Onal C, Ozyigit G, Akgun Z, Atalar B, Igdem S, Oymak E, Agaoglu F, Selek U, Guler OC, Hurmuz P, Mustafayev TZ, Akyol F (2021) Oligometastatic bone disease in castration-sensitive prostate cancer patients treated with stereotactic body radiotherapy using 68Ga-PSMA PET/CT: TROD 09–004 study. Clin Nucl Med 46(6):465–470. https://doi.org/10.1097/RLU.0000000000003558
doi: 10.1097/RLU.0000000000003558
pubmed: 33661210
Rogowski P, Trapp C, von Bestenbostel R, Schmidt-Hegemann NS, Shi R, Ilhan H, Kretschmer A, Stief C, Ganswindt U, Belka C, Li M (2021) Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol 16(1):125. https://doi.org/10.1186/s13014-021-01849-8
doi: 10.1186/s13014-021-01849-8
pubmed: 34193194
pmcid: 8247211
Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L, Livi L, Magrini SM, Salgarello M, Alongi F (2021) Metastasis-directed therapy (SBRT) guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer 19(3):230–236. https://doi.org/10.1016/j.clgc.2020.08.002
doi: 10.1016/j.clgc.2020.08.002
pubmed: 32863189
Alongi F, Fersino S, GiajLevra N, Mazzola R, Ricchetti F, Fiorentino A, Ruggieri R, Malfatti V, Cavalleri S, Salgarello M (2015) Impact of 18F-Choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med 40(11):e496-500. https://doi.org/10.1097/RLU.0000000000000841
doi: 10.1097/RLU.0000000000000841
pubmed: 26053712